Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TRACON Pharmaceuticals, Inc.    TCON

TRACON PHARMACEUTICALS, INC.

(TCON)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

TRACON to Report Fourth Quarter and Full Year 2019 Financial Results and Company Highlights on February 27, 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
02/20/2020 | 06:01pm EDT

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2019 financial and operating results after the close of U.S. financial markets on Thursday, February 27, 2020. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly and full year financial results.

Conference call and webcast:
Date:February 27, 2020
Time:4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in:(855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode:3228345
Via web:www.traconpharma.com; “Events and Presentations” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 nanobody  to be developed for the treatment of sarcoma; DE-122, the ophthalmic formulation of carotuximab, an endoglin antibody that is being developed for patients with wet AMD through a license to Santen Pharmaceutical Company Ltd.; TRC102, a small molecule drug being developed for the treatment of lung cancer; TRC253, a small molecule drug being developed for the treatment of prostate cancer; and TJ004309, a CD73 antibody being developed for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:Investor Contact:
Mark WigginsAndrew McDonald
Chief Business OfficerLifeSci Advisors LLC
(858) 251-3492646-597-6987
mwiggins@traconpharma.comAndrew@lifesciadvisors.com

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TRACON PHARMACEUTICALS, IN
03/19TRACON PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Other ..
AQ
03/19TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of..
GL
03/16TRACON ANNOUNCES SUBMISSION OF REQUE : A Potential Pivotal Study of Envafolimab ..
GL
03/13TRACON PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8..
AQ
03/10TRACON PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
03/09TRACON PHARMACEUTICALS : Santen and TRACON Discontinue Development of DE-122 for..
AQ
02/28TRACON PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
02/28TRACON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
02/27TRACON : 4Q Earnings Snapshot
AQ
02/27TRACON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
More news
Financials (USD)
Sales 2020 -
EBIT 2020 -16,6 M
Net income 2020 -17,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -0,42x
P/E ratio 2021 -0,58x
Capi. / Sales2020 infx
Capi. / Sales2021 8,33x
Capitalization 9,18 M
Chart TRACON PHARMACEUTICALS, INC.
Duration : Period :
TRACON Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRACON PHARMACEUTICALS, IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,67  $
Last Close Price 1,70  $
Spread / Highest target 547%
Spread / Average Target 292%
Spread / Lowest Target 76,5%
EPS Revisions
Managers
NameTitle
Charles P. Theuer President, CEO, CFO & Director
Bonne J. Adams Senior Vice President-Clinical Operations
James R. Twiford Independent Director
William R. LaRue Independent Director
Martin A. Mattingly Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TRACON PHARMACEUTICALS, INC.-40.17%9
GILEAD SCIENCES11.59%94 124
VERTEX PHARMACEUTICALS2.98%61 693
REGENERON PHARMACEUTICALS32.27%53 154
WUXI APPTEC CO., LTD.1.90%21 017
GENMAB A/S-7.05%13 229